Immunologic Mechanisms in Mosquito Allergy: Correlation of Skin Reactions with Specific IgE and IgG Antibodies and Lymphocyte Proliferation Response to Mosquito Antigens-Reference-Cited by-同舟云学术

Immunologic Mechanisms in Mosquito Allergy: Correlation of Skin Reactions with Specific IgE and IgG Antibodies and Lymphocyte Proliferation Response to Mosquito Antigens

Published:1996-09 Issue:3 Volume:77 Page:238-244
ISSN:1081-1206
Container-title:Annals of Allergy, Asthma & Immunology
language:en
Short-container-title:Annals of Allergy, Asthma & Immunology

Author:

Peng Zhikang,Yang Ming,Simons F Estelle R

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy,Immunology

Reference41 articles.

1. Biting insects;Frazier;Arch Dermatol,1973

2. Asthma from mosquito bites: a case report;Gluck;Ann Allergy,1986

3. Mosquito bite anaphylaxis: immunotherapy with whole body extracts;McCormack;Ann Allergy Asthma Immunol,1995

4. Correlation of Aedes albopictus bite reaction with IgE antibody assay and lymphocyte transformation test to mosquito salivary antigens;Oka;J Dermatol,1989

5. Immunology and treatment of mosquito bites;Reunala;Clin Exp Allergy,1990

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Makabuhay (Tinospora rumphii) 25% Cream Versus Hydrocortisone 1% Cream in the Management of Mosquito Bite Reactions: Randomized Double-Blind Controlled Trial;JMIR Dermatology;2023-11-08

2. IgE response to Aed al 13 and Aed al 14 recombinant allergens from Aedes albopictus saliva in humans;World Allergy Organization Journal;2023-11

3. Antibodies to Aedes spp. salivary proteins: a systematic review and pooled analysis;Frontiers in Tropical Diseases;2023-11-01

4. The efficacy and safety of Makabuhay (Tinospora rumpphi) 25% cream vs hydrocortisone 1% cream in the management of mosquito bite reactions: randomized, double blind controlled trial (Preprint);2023-06-28

5. Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial;eBioMedicine;2022-12